Resources

Our 2021 Annual Report documents our medicine development progress, highlights our achievements over the year, and presents our approach to looking forward and continuing our global presence.

December 2021

Learn about new lymphatic filariasis data for moxidectin, progress in clinical development, team expansion, awards and more.

‍

September 2021

Learn about MDGH's expanded footprint, its progress in clinical development, a social impact investment opportunity, and the nominations for the Prix Galien Award for 2021

June 2021

A look at the 2020 MDGH Annual Report, clinical development updates, and the development of a new formulation of moxidectin for children.

March 2021

Learn more about MDGH's plans for its new investigational treatment for tuberculosis and leprosy types 2 reactions.

MDGH celebrated its 15th anniversary in 2020. Our 2020 Annual Report documents our progress as well as our current thinking on our contribution to neglected disease R&D and access to medicines.

Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392(10154):1207-1216

Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953.

Kinrade SA, Mason JW, Sanabria CR, et al. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. Clin Transl Sci. 2018;11(6):582-589.

Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother.2011;55(11):5200-5204.

Korth-Bradley JM, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L. Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin. Clin Pharmacol Drug Dev. 2012;1(1):32-37.

Prichard RK, Geary TG. Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2019;10:69-83.

Boussinesq M, Fobi G, Kuesel AC. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Health. 2018;10(suppl_1):i40-i48.

Milton P, Hamley JID, Walker M, Basanez MG. Moxidectin: an oral treatment for human onchocerciasis. Expert Rev Anti Infect Ther. 2020:1-15. 10.1080/14787210.2020.1792772

Turner HC, Walker M, Attah SK, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015;8:167.

Towards a simplified scabies treatment. Clinical development of a new single-dose oral treatment that has the potential to enhance patient compliance, alleviate suffering, and contribute to reducing the prevalence and transmission of scabies.

‍

Developing a new treatment for Lymphatic Filariasis. A medicine with the potential to support the goal of elimination of Lymphatic Filariasis as a public health problem.

‍

The end of river blindness is in sight. Moxidectin is a new treatment for river blindness. It kills baby worms, reduces the potential for transmission, and can facilitate accelerated disease control and elimination.

Developing a new Treatment for Leprosy Type 2 Reaction. A new treatment with the potential to alleviate suffering, improve outcomes and ensure patients have access to this much needed medicine.

‍